FIELD: medicine.
SUBSTANCE: offered method implying treatment of chronic obstructive lung disease by inhalation of dry powder (versions). Offer is characterized by the fact that powder consists of phormotherol or its salt, solvate or solvate of specified salt, and consisting of single particles pharmaceutically acceptable solvent or carrier in amount 400 to 5000 mcg per 1 mcg of active component, taking into consideration that carrier or solvent have average particle size 40 to 100 mcm.
EFFECT: continuous broncholytic action and good safety profile.
10 cl, 1 tbl, 30 ex
| Title | Year | Author | Number |
|---|---|---|---|
| NOVEL APPLICATION OF BUDESONIDE AND FORMOTEROL | 1998 |
|
RU2199322C2 |
| MEDICINAL AGENT AND PHARMACEUTICAL SET DESIGNATED FOR ASTHMA TREATMENT | 2000 |
|
RU2270670C2 |
| COMPOSITIONS INCLUDING FORMOTEROL AND FLUCTICASON PROPIONATE INDICATED FOR TREATING ASTHMA | 2000 |
|
RU2249454C2 |
| COMPOSITIONS COMPRISING FORMOTEROL AND THIOTROPIUM SALT | 2000 |
|
RU2238085C2 |
| COMBINATION AND PHARMACEUTICAL PREPARATION FOR TREATING INFLAMMATORY AND OBSTRUCTIVE RESPIRATORY DISEASES | 2005 |
|
RU2438660C2 |
| NEW DOSE AND FORMULATION | 2009 |
|
RU2608713C2 |
| USING FORMOTEROL AND BUDESONIDE-CONTAINING COMPOSITION FOR ACUTE ASTHMA STATE TREATMENT | 1999 |
|
RU2222332C2 |
| INHALATION PREPARATION FOR TREATING BRONCHAIL ASTHMA AND CHRONIC OBSTRUCTIVE PULMONARY DISEASE AND METHOD FOR PREPARING IT | 2012 |
|
RU2504382C1 |
| INHALATION PREPARATION FOR TREATING BRONCHIAL ASTHMA AND CHRONIC OBSTRUCTIVE PULMONARY DISEASE AND METHOD FOR PREPARING IT | 2012 |
|
RU2510267C2 |
| PHARMACEUTICAL COMPOSITION | 2011 |
|
RU2642624C2 |
